ZUSDURI (Mitomycin) Patent Expiration, LOE Window & CMS Spending

ZUSDURI (Mitomycin) by Urogen: FDA Orange Book core substance LOE 2031-01-20 (last listed 2044-07-25), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $21,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUrogen
FDA Application & PathwayN215793 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-01-20
Last Listed Patent or Exclusivity Date2044-07-25
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($21,500 intro WAC)